IO

IO Biotech, Inc.

  • CIK: 0001865494
  • EIN: 87-0909276
  • Business address: OLE MAALOES VEH 3, COPENHAGEN, Denmark, 2200

Information

  • Mailing address
    OLE MAALOES VEH 3, COPENHAGEN, Delaware, 2200
  • Phone
    4570702980
  • State location
    Denmark
  • State of incorporation
    Delaware
  • Fiscal year end
    December 31
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About IO Biotech, Inc.

IO Biotech, Inc. (CIK: 0001865494) is an American company incorporated in the state of Denmark. Head office is located at OLE MAALOES VEH 3, COPENHAGEN, Denmark, 2200. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. IO Biotech, Inc. is a public company and trade via Over-The-Counter (OTC).

Ownership

Owner Filings Transaction Date Type of Owner
Hunter Heidi 0001891841 Aug-11-2023 director
Vivo Opportunity, LLC 0001728970 Aug-09-2023 10 percent owner
Smith Devin Whittemore 0001747818 Aug-09-2023 officer: General Counsel
Vivo Opportunity Fund Holdings, L.P. 0001930214 Aug-09-2023 10 percent owner
Kurma Partners 0001989692 Aug-09-2023 10 percent owner
Ahmad Qasim Iftikhar 0001985801 Jul-15-2023 officer: Chief Medical Officer
Sullivan Amy 0001887865 Mar-17-2023 officer: Chief Financial Officer
Burkavage Brian 0001865633 May-11-2022 officer: Chief Accounting Officer
Smith David V 0001229447 Mar-01-2022 director
HBM Healthcare Investments (Cayman) Ltd. 0001232258 Nov-04-2021 10 percent owner
Novo Holdings A/S 0001388325 Nov-04-2021 10 percent owner
Lundbeckfond Invest A/S 0001591046 Nov-04-2021 10 percent owner
Nielsen Jack 0001602402 Nov-04-2021 director
Glaub Kathleen Sereda 0001619612 Nov-04-2021 director
Vendola Keith A. 0001740994 Nov-04-2021 officer: Chief Financial Officer
Vivo Capital Fund IX, L.P. 0001750117 Nov-04-2021 10 percent owner
Vivo Capital IX, LLC 0001750698 Nov-04-2021 10 percent owner
Hirth Peter 0001813780 Nov-04-2021 director
Belawat Priyanka 0001816209 Nov-04-2021 director
Andersson Claus A. 0001890710 Nov-04-2021 director
Zocca Mai-Britt 0001890736 Nov-04-2021 director, officer: Chief Executive Officer
Elling Christian E 0001891306 Nov-04-2021 director
Ehrnrooth Eva 0001891333 Nov-04-2021 officer: Chief Medical Officer
Coutanceau Emmanuelle 0001891499 Nov-04-2021 director
Malier Vanessa 0001891515 Nov-04-2021 director
Al-Hajj Muhammad 0001892300 Nov-04-2021 officer: Chief Scientific Officer

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by IO Biotech, Inc.

Filings Format Description Filed/Effective File/Film Number
SCHEDULE 13D/A Document Acc-no: 0001415889-25-022324 (34 Act) Size: KB Aug-19-2025

005-93023

251232830
10-Q Document

Quarterly report pursuant to sections 13 or 15(d)

Acc-no: 0001193125-25-180860 (34 Act) Size: KB		 Aug-14-2025

001-41008

251220347
8-K Document

Current report filing

Acc-no: 0001193125-25-180830 (34 Act) Size: KB		 Aug-14-2025

001-41008

251219974
8-K Document

Current report filing

Acc-no: 0001193125-25-177471 (34 Act) Size: KB		 Aug-11-2025

001-41008

251200246
EFFECT Document Acc-no: 9999999995-25-002438 (33 Act) Size: KB Jul-31-2025

333-288936

251173507
CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001193125-25-168423 ( Act) Size: KB		 Jul-29-2025

UPLOAD Document Acc-no: 0000000000-25-007962 ( Act) Size: KB Jul-29-2025

333-288936
S-3 Document

Registration statement for specified transactions by certain issuers

Acc-no: 0001193125-25-164495 (33 Act) Size: KB		 Jul-24-2025

333-288936

251147945
8-K Document

Current report filing

Acc-no: 0001193125-25-151511 (34 Act) Size: KB		 Jun-27-2025

001-41008

251088077
8-K Document

Current report filing

Acc-no: 0001193125-25-143658 (34 Act) Size: KB		 Jun-20-2025

001-41008

251061525
EFFECT Document Acc-no: 9999999995-25-001891 (33 Act) Size: KB Jun-11-2025

333-287554

251041568
CORRESP Document

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Acc-no: 0001193125-25-137907 ( Act) Size: KB		 Jun-09-2025

8-K Document

Current report filing

Acc-no: 0001193125-25-137894 (34 Act) Size: KB		 Jun-09-2025

001-41008

251034879
4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002034 ( Act) Size: 0 KB		 Jun-06-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002033 ( Act) Size: 0 KB		 Jun-06-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002032 ( Act) Size: 0 KB		 Jun-06-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002031 ( Act) Size: 0 KB		 Jun-06-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002030 ( Act) Size: 0 KB		 Jun-06-2025

4 Document

Statement of changes in beneficial ownership of securities

Acc-no: 0000905148-25-002029 ( Act) Size: 0 KB		 Jun-06-2025

8-K Document

Current report filing

Acc-no: 0001193125-25-134502 (34 Act) Size: KB		 Jun-04-2025

001-41008

251021999

Recent 20 filings. View all IO Biotech, Inc. filings

Reviews

Overall rating 5.0

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Frequently Asked Questions

Tags:

  • IO Biotech, Inc. overview
  • IO Biotech, Inc. job
  • IO Biotech, Inc. stock
  • IO Biotech, Inc. ownership
  • IO Biotech, Inc. CEO
  • IO Biotech, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

atai Life Sciences Luxembourg S.A.
Update: Sep 23, 2025
Hyperliquid Strategies Inc
Update: Sep 05, 2025
Polaryx Therapeutics, Inc.
Update: Sep 05, 2025
Nasus Pharma Ltd
Update: Jul 10, 2025
Promicell, Inc.
Update: May 30, 2025
Maius Pharmaceutical Group Co., Ltd.
Update: Mar 01, 2025

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 3356 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 1252 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 1401 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 4265 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 2441 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 4665 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 2254 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 4176 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 4779 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by